FDA Accepts Vanda Pharmaceuticals’ BLA for Imsidolimab in Generalized Pustular Psoriasis

The FDA has assigned a PDUFA target action date of December 12, 2026 … News release. PR Newswire. Published February 25, 2026. Accessed …

By AJDesign77|2026-02-25T17:32:12+00:00February 25th, 2026|Uncategorized|0 Comments

About the Author: AJDesign77

Related Posts

US Customs and Border Protection official says new process for tariff refunds could be ready …
US Customs and Border Protection official says new process for tariff refunds could be ready …
FDA’s Controversial Vaccine Chief Is Leaving the Agency … Again – MedPage Today
FDA’s Controversial Vaccine Chief Is Leaving the Agency … Again – MedPage Today
FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
US Tells Tariff Refund Judge It Can’t Comply With Order – Bloomberg
US Tells Tariff Refund Judge It Can’t Comply With Order – Bloomberg
Court overturns Trump tariffs, leading to refunds for thousands | Watch – MSN
Court overturns Trump tariffs, leading to refunds for thousands | Watch – MSN